TSE:ONC

Oncolytics Biotech Inc. (ONC.TO) Stock Forecast, Price & News

C$4.22

+0.13 (+3.18 %)

(As of 03/1/2021 02:39 PM ET)

Add

Compare

Today's Range

C$4.12

Now: C$4.22▼

C$4.26

50-Day Range

C$3.07

MA: C$3.58▼

C$4.85

52-Week Range

C$1.35

Now: C$4.22▼

C$5.95

Volume188,340 shs

Average Volume302,918 shs

Market CapitalizationC$182.72 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Headlines

5 Penny Stocks To Watch This Week If Biotech Is Your Focus In February
February 24, 2021 | marketwatch.com

Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021
February 17, 2021 | finance.yahoo.com

Oncolytic Virus Immunotherapy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
February 12, 2021 | marketwatch.com

Pancreatic Cancer Market Overview, Sales Revenue, Opportunities, Size, Share, Competitive Landscape and Comprehensive Research Study 2024
January 17, 2021 | marketwatch.com

Nymi survey reveals the majority of Americans would welcome using a wearable at work, as companies seek technology to plan for safe returns to workplaces
January 13, 2021 | finance.yahoo.com

Top Penny Stocks To Buy According To Analysts With 42%-291% Targets
January 8, 2021 | marketwatch.com

Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
December 9, 2020 | finance.yahoo.com

Thinking about buying stock in Pfizer, Nio, Lexicon Pharmaceuticals, Oncolytics Biotech, or Boeing?
December 8, 2020 | marketwatch.com

Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace
December 6, 2020 | benzinga.com

Is Oncolytics Biotech, Inc. (ONCY) A Good Stock To Buy?
November 26, 2020 | finance.yahoo.com

Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
November 9, 2020 | finance.yahoo.com

Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
October 27, 2020 | prnewswire.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:ONC

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.oncolyticsbiotech.com

Phone+1-403-6707380

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity Ratio2.46

Current Ratio9.09

Quick Ratio7.98

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowC$0.64 per share

Price / Cash Flow6.63

Book ValueC$0.50 per share

Price / Book8.53

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares43,299,000

Market CapC$182.72 million

Next Earnings Date3/5/2021 (Confirmed)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.25 out of 5 stars

3.3 Analyst's Opinion

Consensus Rating
Oncolytics Biotech Inc. (ONC.TO) has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$6.00, Oncolytics Biotech Inc. (ONC.TO) has a forecasted upside of 45.3% from its current price of C$4.13.
Amount of Analyst Coverage
Oncolytics Biotech Inc. (ONC.TO) has only been the subject of 2 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Oncolytics Biotech Inc. (ONC.TO) has received 179 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Oncolytics Biotech Inc. (ONC.TO) has received 129 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Oncolytics Biotech Inc. (ONC.TO) has received 58.12% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech Inc. (ONC.TO) and other stocks. Vote “Outperform” if you believe ONC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Oncolytics Biotech Inc. (ONC.TO) does not currently pay a dividend.
Dividend Growth
Oncolytics Biotech Inc. (ONC.TO) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncolytics Biotech Inc. (ONC.TO) insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oncolytics Biotech Inc. (ONC.TO) is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncolytics Biotech Inc. (ONC.TO) is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncolytics Biotech Inc. (ONC.TO) has a P/B Ratio of 8.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

C$4.22

+0.13 (+3.18 %)

(As of 03/1/2021 02:39 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Oncolytics Biotech Inc. (ONC.TO) (TSE:ONC) Frequently Asked Questions

Is Oncolytics Biotech Inc. (ONC.TO) a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech Inc. (ONC.TO) in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Oncolytics Biotech Inc. (ONC.TO) stock.
View analyst ratings for Oncolytics Biotech Inc. (ONC.TO) or view top-rated stocks.

What stocks does MarketBeat like better than Oncolytics Biotech Inc. (ONC.TO)?

Wall Street analysts have given Oncolytics Biotech Inc. (ONC.TO) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncolytics Biotech Inc. (ONC.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oncolytics Biotech Inc. (ONC.TO)'s next earnings date?

Oncolytics Biotech Inc. (ONC.TO) is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Oncolytics Biotech Inc. (ONC.TO).

How has Oncolytics Biotech Inc. (ONC.TO)'s stock price been impacted by Coronavirus (COVID-19)?

Oncolytics Biotech Inc. (ONC.TO)'s stock was trading at C$2.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONC shares have increased by 75.9% and is now trading at C$4.17.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ONC?

3 Wall Street analysts have issued 1 year price objectives for Oncolytics Biotech Inc. (ONC.TO)'s stock. Their forecasts range from C$6.00 to C$6.00. On average, they anticipate Oncolytics Biotech Inc. (ONC.TO)'s stock price to reach C$6.00 in the next twelve months. This suggests a possible upside of 43.9% from the stock's current price.
View analysts' price targets for Oncolytics Biotech Inc. (ONC.TO) or view top-rated stocks among Wall Street analysts.

Who are Oncolytics Biotech Inc. (ONC.TO)'s key executives?

Oncolytics Biotech Inc. (ONC.TO)'s management team includes the following people:

Dr. Matthew C. Coffey, Pres, CEO & Director
Mr. Kirk J. Look C.A., CA, Chief Financial Officer
Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 54, Pay $544.58k)
Mr. John Mark Lievonen B.B.A., F.C.A., M.B.A., CM, FCPA, FCA, LLD, Consultant
Dr. Thomas C. Heineman M.D., Ph.D., Global Head of Clinical Devel. & Operations
Jon Patton, Director of Investor Relations & Communication
Dr. Grey Wilkinson Ph.D., Scientist of Translational Medicine
Dr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 73)

Who are some of Oncolytics Biotech Inc. (ONC.TO)'s key competitors?

Some companies that are related to Oncolytics Biotech Inc. (ONC.TO) include Ergomed (ERGO), Biotest Aktiengesellschaft (BIO), Inventiva (IVA), NexImmune (NEXI), Terns Pharmaceuticals (TERN), Landos Biopharma (LABP), Novacyt S.A. (NCYT.L) (NCYT), Angion Biomedica (ANGN), Silence Therapeutics plc (SLN.L) (SLN), Sensei Biotherapeutics (SNSE), Burcon NutraScience Co. (BU.TO) (BU), 22nd Century Group (XXII), Decibel Therapeutics (DBTX), Aptose Biosciences (APS) and Pfenex (PFNX).
View all of ONC's competitors.

What other stocks do shareholders of Oncolytics Biotech Inc. (ONC.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech Inc. (ONC.TO) investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix Corp. (RVX.TO) (RVX), Ballard Power Systems (BLDP), (ECA), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy Ltd. (BIR.TO) (BIR), Enbridge (ENB) and First Majestic Silver Corp. (FR.TO) (FR).

What is Oncolytics Biotech Inc. (ONC.TO)'s stock symbol?

Oncolytics Biotech Inc. (ONC.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech Inc. (ONC.TO)?

Shares of ONC and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech Inc. (ONC.TO)'s stock price today?

One share of ONC stock can currently be purchased for approximately C$4.17.

How much money does Oncolytics Biotech Inc. (ONC.TO) make?

Oncolytics Biotech Inc. (ONC.TO) has a market capitalization of C$180.56 million.

What is Oncolytics Biotech Inc. (ONC.TO)'s official website?

The official website for Oncolytics Biotech Inc. (ONC.TO) is www.oncolyticsbiotech.com.

Where are Oncolytics Biotech Inc. (ONC.TO)'s headquarters?

Oncolytics Biotech Inc. (ONC.TO) is headquartered at 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada.

How can I contact Oncolytics Biotech Inc. (ONC.TO)?

Oncolytics Biotech Inc. (ONC.TO)'s mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.

This page was last updated on 3/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here